Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
PPV-06 immunotherapy targets interleukin-6 (IL-6), a key molecule of the immune system whose
overproduction is implicated in many inflammatory and autoimmune diseases such as rheumatoid
arthritis and osteoarthritis. The benefit of vaccination with PPV-06 is to induce, in
response to immunizations, the production of antibodies directed against IL-6. The antibodies
produced will neutralize the biological activity of IL-6 involved in the body's inflammatory
process.
The primary objective is to evaluate the safety/tolerability of vaccination with PPV-06.